Originally posted here:
Novo Nordisk's sales increased by 22% in Danish kroner and by 24% at constant exchange rates to DKK 65.3 billion in the first three months of 2024
Related Post
- Kane Biotech Expands its Wound Care Portfolio with Patented Schultz Biofilm Wound Map - May 15th, 2024
- Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member - May 15th, 2024
- Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia - May 15th, 2024
- Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024 - May 15th, 2024
- CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates - May 15th, 2024
- Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates - May 15th, 2024
- Tonix Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase - May 15th, 2024
- Third Harmonic Bio Announces First Quarter 2024 Financial Results and Provides Business Update - May 15th, 2024
- Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis - May 15th, 2024
- PDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results - May 15th, 2024
- Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights - May 15th, 2024
- Abstract on Phase 2 Study with IMUNON’s IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual... - May 15th, 2024
- Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Clinical Trial for High Quality Weight Loss - May 15th, 2024
- PaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101 - May 15th, 2024
- Medigene Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS - May 15th, 2024
- Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement - May 15th, 2024
- Yield10 Bioscience Announces Delisting from Nasdaq - May 15th, 2024
- Novartis highlights pioneering innovation in CML with data from Scemblix® Phase III ASC4FIRST study in newly diagnosed patients at ASCO and EHA - May 15th, 2024
- Alvotech S.A. Annual General Meeting to be held June 7, 2024 - May 15th, 2024
- PHAXIAM provides Business and Financial Update for the First Quarter of 2024 - May 15th, 2024
- Avalyn Announces Multiple Presentations on its Lead Program, AP01, for Pulmonary Fibrosis and its Approach to Developing Novel Inhaled Therapies for... - May 13th, 2024
- IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ASGCT 2024 - May 13th, 2024
- Artelo Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update - May 13th, 2024
- Oncocyte to Announce First Quarter 2024 Financial Results - May 13th, 2024
- Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference - May 13th, 2024
- Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT) - May 13th, 2024
- Science 37 Metasite™ Undergoes Successful FDA Inspection, Marking Major Milestone in Virtual Site Quality Assurance and Compliance - May 13th, 2024
- Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair... - May 13th, 2024
- Humacyte to Participate at Upcoming Investor Conferences in May - May 13th, 2024
- X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference - May 13th, 2024
- Terns Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Updates - May 13th, 2024
- Jasper Therapeutics Announces Briquilimab Development Program in Asthma - May 13th, 2024
- Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies... - May 13th, 2024
- Benitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational Update - May 13th, 2024
- TransCode Therapeutics Open Letter to Shareholders - May 13th, 2024
- Biomerica Announces inFoods® IBS Pilot Launch with Prominent 1,100 Member Physician Group Commencing June 2024 - May 13th, 2024
- Abliva to Host Virtual KOL Event on KL1333 in Primary Mitochondrial Disease on May 21, 2024 - May 13th, 2024
- Significant and Sustained Improvements in Renal Function Reported for Adults with Chronic Hypoparathyroidism Treated with TransCon™ PTH... - May 13th, 2024
- Relay Therapeutics to Host New Program and Platform Event on June 6, 2024 - May 13th, 2024
- Checkpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference - May 13th, 2024
- Ocugen to Present at May 2024 Investor Conferences - May 11th, 2024
- PharmaTher Announces Assigned FDA Approval Goal Date of its Priority Original Abbreviated New Drug Application for Ketamine - May 11th, 2024
- Praxis Precision Medicines to Report First Quarter 2024 Financial Results on Monday, May 13, 2024 - May 11th, 2024
- Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update - May 11th, 2024
- Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product - May 11th, 2024
- iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates - May 11th, 2024
- Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates - May 11th, 2024
- CorMedix Inc. to Participate in Two Upcoming Investor Conferences - May 11th, 2024
- Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation - May 11th, 2024
- Artelo Biosciences to Present at the Pharma Partnering Summit 2024 on May 14th - May 11th, 2024
- Nika Pharmaceuticals, Inc. (NIKA) Acquires a Two Million USD Production Building - May 11th, 2024
- CannaCon West Coming to the Albuquerque Convention Center in May 2024 - May 11th, 2024
- Optinose Announces Reporting Date for First Quarter 2024 Financial Results - May 11th, 2024
- Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam - May 11th, 2024
- Assertio to Present at the Citizens JMP Life Sciences Conference in New York City - May 11th, 2024
- Ocugen Announces Distribution of Series C Preferred Stock to Holders of its Common Stock - May 11th, 2024
- Longeveron Announces Board of Directors Planned Transitions - May 11th, 2024
- Evaxion Receives Nasdaq Notification - May 11th, 2024
- Entera Bio Reports Q1 2024 Financial Results and Provides Business Updates - May 11th, 2024
- Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives - May 11th, 2024
- Gritstone bio Reports First Quarter 2024 Financial Results and Provides Corporate Updates - May 10th, 2024
- INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update - May 10th, 2024
- Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights - May 10th, 2024
- Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP) - May 10th, 2024
- Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures - May 10th, 2024
- Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update - May 10th, 2024
- Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations - May 10th, 2024
- Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates - May 10th, 2024
- Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update - May 10th, 2024
- DBV Technologies to Participate in Upcoming Investor Conferences - May 10th, 2024
- Tempest Reports First Quarter 2024 Financial Results and Provides Business Update - May 10th, 2024
- Theratechnologies Reports on its Annual Meeting of Shareholders - May 10th, 2024
- BioSyent Schedules Q1 2024 Earnings Release for May 16, 2024 - May 10th, 2024
- Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress - May 10th, 2024
- Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress - May 10th, 2024
- vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update - May 10th, 2024
- 23andMe to Report Q4 and Full Year FY2024 Financial Results - May 10th, 2024
- PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer - May 10th, 2024
- Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference - May 10th, 2024
- Inotiv, Inc. Reschedules its Fiscal 2024 Second Quarter Results - May 10th, 2024
Recent Comments